Clinical Trials · NCT02843399
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 15,498
- Start date
- Aug 2016
- Locations
- 1 site, United States
- Primary endpoint
- Diabetes-related HCRU/costs